HC Wainwright upgraded shares of Diffusion Pharmaceuticals (NASDAQ:DFFN – Get Rating) from a neutral rating to a buy rating in a research note published on Tuesday morning, The Fly reports. HC Wainwright currently has $9.50 price objective on the stock.

Separately, StockNews.com upgraded shares of Diffusion Pharmaceuticals from a sell rating to a hold rating in a report on Monday.

Diffusion Pharmaceuticals Price Performance

NASDAQ DFFN opened at $6.90 on Tuesday. Diffusion Pharmaceuticals has a 12 month low of $5.10 and a 12 month high of $31.50. The firm has a market capitalization of $14.07 million, a PE ratio of -0.56 and a beta of 1.59. The company's 50 day simple moving average is $7.34 and its 200 day simple moving average is $12.46.

Institutional Trading of Diffusion Pharmaceuticals

About Diffusion Pharmaceuticals

(Get Rating)

Diffusion Pharmaceuticals Inc, a biopharmaceutical company, develops novel therapies that enhance the body's ability to deliver oxygen. Its lead product candidate is Trans Sodium Crocetinate that is developed to enhance the diffusion of oxygen to tissues, as well as to treat COVID-19 disease. Diffusion Pharmaceuticals Inc was founded in 2001 and is based in Charlottesville, Virginia.

Read More

• Get a free copy of the StockNews.com research report on Diffusion Pharmaceuticals (DFFN)
• Are These 3 Video Game Stocks Now In Play?
• 2 Long-Term EV Plays Trading Under $20
• Exxon, Occidental Petroleum Lead Heavy Month Of Insider Buying
• Why Apple is Primed to Take a Bite Out of Live Sports
• Home Depot Results Point To Sluggish 2nd Half

Receive News & Ratings for Diffusion Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Diffusion Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.